subscribeSubscribe
GSK’s Omjjara Receives Japanese Approval For Myelofibrosis Treatment

GSK’s Omjjara Receives Japanese Approval For Myelofibrosis Treatment
PHARMABIZ
25 Jun 2024
Share Share
European Commission authorises GSK’s Omjjara (momelotinib)

European Commission authorises GSK’s Omjjara (momelotinib)
PRESS RELEASE
29 Jan 2024
Share Share
OJJAARA™ (momelotinib) Now Available from Onco360 For MF

OJJAARA™ (momelotinib) Now Available from Onco360 For MF
BUSINESSWIRE
25 Sep 2023
Share Share
US FDA approves GSK`s bone marrow cancer therapy

US FDA approves GSK`s bone marrow cancer therapy
REUTERS
16 Sep 2023
Share Share
Combination Therapies May Spur Evolution of the Myelofibrosis Treatment Paradigm

Combination Therapies May Spur Evolution of the Myelofibrosis Treatment Paradigm
Ruxolitinib ONCLIVE
22 Jun 2023
Share Share
FDA delays approval decision on GSK`s $1.9B blood cancer bet

FDA delays approval decision on GSK`s $1.9B blood cancer bet
Nick Paul Taylor FIERCE BIOTECH
17 Jun 2023
Share Share
New data at ASH underscore the potential for durable responses with momelotinib

New data at ASH underscore the potential for durable responses with momelotinib
BUSINESSWIRE
11 Dec 2022
Share Share
ASH: GSK explores new avenues for JAK drug from $1.9B Sierra buy

ASH: GSK explores new avenues for JAK drug from $1.9B Sierra buy
Angus Liu FIERCEBIOTECH
11 Dec 2022
Share Share
EMA accepts momelotinib marketing application

EMA accepts momelotinib marketing application
EUROPEANPHARMACEUTICALREVIEW
05 Dec 2022
Share Share
GSK’s two new cancer drugs look promising

GSK’s two new cancer drugs look promising
PHARMAFILE
03 Dec 2022
Share Share